Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) Operating Expenses (2019 - 2025)

Volitionrx's Operating Expenses history spans 9 years, with the latest figure at $5.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses fell 11.85% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $23.5 million, down 16.96%, while the annual FY2025 figure was $23.5 million, 16.96% down from the prior year.
  • Operating Expenses reached $5.3 million in Q4 2025 per VNRX's latest filing, down from $5.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $9.8 million in Q2 2023 to a low of $5.3 million in Q4 2025.
  • Average Operating Expenses over 5 years is $7.4 million, with a median of $7.7 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: skyrocketed 68.43% in 2021, then crashed 33.52% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $8.8 million in 2021, then fell by 7.6% to $8.1 million in 2022, then rose by 10.51% to $9.0 million in 2023, then plummeted by 33.52% to $6.0 million in 2024, then decreased by 11.85% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for VNRX's Operating Expenses are $5.3 million (Q4 2025), $5.7 million (Q3 2025), and $6.7 million (Q2 2025).